Alexion/P&G Pexelizumab Failed Phase III Could Compromise Partnership
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A development partnership between Alexion and Procter & Gamble could be called into question following negative results of two Phase III trials of the terminal complement inhibitor pexelizumab